Ascendis Pharma Endocrinology Division A/S
7
2
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
57%
4 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Role: lead
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Role: lead
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Role: lead
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Role: lead
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Role: lead
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Role: lead
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Role: lead
All 7 trials loaded